103 related articles for article (PubMed ID: 16364390)
1. The color appearance of stimuli detected via short-wavelength-sensitive cones for breast cancer survivors using tamoxifen.
Eisner A; Incognito LJ
Vision Res; 2006 May; 46(11):1816-22. PubMed ID: 16364390
[TBL] [Abstract][Full Text] [Related]
2. The color appearance of stimuli detected via short-wavelength-sensitive cones: comparisons with visual adaptation and visual field data for peri- or post-menopausal women under 70 years of age.
Eisner A; Toomey MD
Vision Res; 2008 Nov; 48(26):2663-72. PubMed ID: 18343478
[TBL] [Abstract][Full Text] [Related]
3. Foveal and non-foveal measures of short wavelength sensitive pathways in glaucoma and ocular hypertension.
Heron G; Adams AJ; Husted R
Ophthalmic Physiol Opt; 1987; 7(4):403-4. PubMed ID: 3454916
[TBL] [Abstract][Full Text] [Related]
4. Multifocal electroretinography, color discrimination and ocular toxicity in tamoxifen use.
Salomão SR; Watanabe SE; Berezovsky A; Motono M
Curr Eye Res; 2007 Apr; 32(4):345-52. PubMed ID: 17453956
[TBL] [Abstract][Full Text] [Related]
5. Small optic cup sizes among women using tamoxifen: assessment with scanning laser ophthalmoscopy.
Eisner A; O'Malley JP; Incognito LJ; Toomey MD; Samples JR
Curr Eye Res; 2006 Apr; 31(4):367-79. PubMed ID: 16603470
[TBL] [Abstract][Full Text] [Related]
6. Transient tritanopia in migraine: evidence for a large-field retinal abnormality in blue-yellow opponent pathways.
Tibber MS; Shepherd AJ
Invest Ophthalmol Vis Sci; 2006 Nov; 47(11):5125-31. PubMed ID: 17065534
[TBL] [Abstract][Full Text] [Related]
7. Retinal hemorrhages in anastrozole users.
Eisner A; Falardeau J; Toomey MD; Vetto JT
Optom Vis Sci; 2008 May; 85(5):301-8. PubMed ID: 18451730
[TBL] [Abstract][Full Text] [Related]
8. Contrasting blue-on-yellow with white-on-white visual fields: Roles of visual adaptation for healthy peri- or postmenopausal women younger than 70 years of age.
Eisner A; Toomey MD; Incognito LJ; O'malley JP; Samples JR
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5605-14. PubMed ID: 17122155
[TBL] [Abstract][Full Text] [Related]
9. Foveal color and luminance sensitivity losses in glaucoma.
Kelly JP; Fourman SM; Jindra LF
Ophthalmic Surg Lasers; 1996 Mar; 27(3):179-87. PubMed ID: 8833122
[TBL] [Abstract][Full Text] [Related]
10. Selectivity of human retinotopic visual cortex to S-cone-opponent, L/M-cone-opponent and achromatic stimulation.
Mullen KT; Dumoulin SO; McMahon KL; de Zubicaray GI; Hess RF
Eur J Neurosci; 2007 Jan; 25(2):491-502. PubMed ID: 17284191
[TBL] [Abstract][Full Text] [Related]
11. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
12. The multifocal pattern electroretinogram (mfPERG) and cone-isolating stimuli.
Langrová H; Jägle H; Zrenner E; Kurtenbach A
Vis Neurosci; 2007; 24(6):805-16. PubMed ID: 18093368
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
Vehmanen L; Elomaa I; Blomqvist C; Saarto T
J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
Kimmick GG; Lovato J; McQuellon R; Robinson E; Muss HB
Breast J; 2006; 12(2):114-22. PubMed ID: 16509835
[TBL] [Abstract][Full Text] [Related]
15. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
[TBL] [Abstract][Full Text] [Related]
16. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.
Gianni L; Panzini I; Li S; Gelber RD; Collins J; Holmberg SB; Crivellari D; Castiglione-Gertsch M; Goldhirsch A; Coates AS; Ravaioli A;
Cancer; 2006 Feb; 106(3):505-13. PubMed ID: 16369994
[TBL] [Abstract][Full Text] [Related]
17. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
19. Short wavelength automated perimetry and tamoxifen use.
Eisner A; Austin DF; Samples JR
Br J Ophthalmol; 2004 Jan; 88(1):125-30. PubMed ID: 14693789
[TBL] [Abstract][Full Text] [Related]
20. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
